白血病/淋巴瘤等血液肿瘤经联合化疗,可以获得完全缓解,但难彻底消灭肿瘤微小残留病(MRD)。基因修饰的树突状细胞瘤苗以其增强肿瘤细胞的免疫原性,启动机体的特异性抗肿瘤免疫应答,成为清除MRD的一种有希望的途径。本文就树突状细胞的生物学特性及其诱导培养,基因转移载体的选择,以及不同来源基因修饰DC诱导抗血液肿瘤的特点等方面的研究进展进行综述。 Leukemia / lymphoma and other hematologic malignancies can be completely relieved by combined chemotherapy, but it is difficult to completely eradicate minimal residual disease (MRD). Genetically modified dendritic cell vaccine, as it enhances the immunogenicity of tumor cells and initiates the body’s specific antitumor immune response, is a promising route to eradicate MRD. In this paper, the biological characteristics of dendritic cells and their induction of culture, gene transfer vector selection, as well as the different sources of gene modified DC-induced anti-hematological malignancies and other aspects of research progress are reviewed.